Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…Abstract Number: 2054 • ACR Convergence 2023
Superiority of Adalimumab in Treating Childhood Chronic Idiopathic Uveitis: Evidence from a Multicentre Experience
Background/Purpose: Childhood Chronic Idiopathic Uveitis (cCIU) is a severe ocular condition that accounts for the 40% of all uveitis in children. Its timely and proper…Abstract Number: 0524 • ACR Convergence 2023
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting more than a third of patients. However, long-term interventional…Abstract Number: 1330 • ACR Convergence 2023
Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial
Background/Purpose: The optimal first-line treatment of patients with early rheumatoid arthritis (eRA) is not established. Methods: In this investigator-initiated, randomized, open-label study (NCT01491815), patients with…Abstract Number: 2161 • ACR Convergence 2023
Pharmacokinetic and Safety Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501
Background/Purpose: ABP 501 has been developed as a biosimilar for Humira® (adalimumab), a fully human monoclonal antibody targeting tumor necrosis factor alpha (TNFα). ABP 501…Abstract Number: 073 • 2023 Pediatric Rheumatology Symposium
Golimumab Therapy in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series Reviewing Safety and Efficacy
Background/Purpose: Chronic Recurrent Multifocal Osteomyelitis (CRMO) is an autoinflammatory bone disease requiring immunosuppressive therapy in half of patients. Monoclonal Tumor Necrosis Factor inhibitors (TNFi) are…Abstract Number: 096 • 2023 Pediatric Rheumatology Symposium
DADA2 – a Case Series from North India
Background/Purpose: We present a series of children previously diagnosed and managed as Polyarteritis nodosa at our unit. Due to ease of availability of mutation analysis…Abstract Number: 0297 • ACR Convergence 2022
Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Background/Purpose: Residual pain remains a challenge that prevents patients (pts) with RA from achieving a better quality of life. Current RA treatments have demonstrated efficacy…Abstract Number: 0866 • ACR Convergence 2022
Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab
Background/Purpose: Pediatric uveitis is commonly associated with rheumatic disease and can lead to sight-threatening complications. Initial treatment are glucocorticoids and subsequently methotrexate (MTX) and TNF…Abstract Number: 1669 • ACR Convergence 2022
Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…Abstract Number: 0315 • ACR Convergence 2022
The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab
Background/Purpose: Comorbid conditions may affect efficacy of treatment in patients with rheumatoid arthritis (RA). The aim of this analysis was to evaluate the impact of…Abstract Number: 0887 • ACR Convergence 2022
Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database
Background/Purpose: Drug persistence represents long-term therapeutic performance in real clinical setting and tuberculosis (TB) is one of the most important adverse events following biological treatments…Abstract Number: 1728 • ACR Convergence 2022
Increased Frequency of Highly Differentiated T Effector Memory Cells Re-expressing CD45RA (Temra) and Cytomegalovirus Seropositivity Are Associated with Persistent Disease Specifically Refractory to Anti-TNF Therapy in Rheumatoid Arthritis
Background/Purpose: Enrichment of highly differentiated T cells have been reported in rheumatoid arthritis (RA) patients compared to healthy individuals. The role of highly differentiated T…Abstract Number: 0372 • ACR Convergence 2022
Incidence and Risk of Overall Infections in Patients with Ankylosing Spondylitis Receiving Biologic Therapies: A Real-world Prospective Observational Study Using KOBIO Registry
Background/Purpose: Infection is a perpetual concern in patients treated with biological therapy. However, long-term real-world data on infectious profile of AS patients are lacking The…Abstract Number: 0934 • ACR Convergence 2022
Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Background/Purpose: The American College of Rheumatology and the European League Against Rheumatism recommend using methotrexate (MTX) with targeted therapy. Previous studies have shown that tapering…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 18
- Next Page »